October 26, 2005 -- Rituxan helped prevent a relapse of indolent non-Hodgkin’s lymphoma; Edwards Lifesciences will resume a trial of its non-invasive alternative to open-heart surgery to replace the aortic valve; Cerimon Pharma acquired US rights to market two topical formulations of a non-steroidal anti-inflammatory drug; Bayer Healthcare and Ortho-McNeil will partner on BAY 59-7939, a treatment for thrombosis; Tanox said a test of TNX-355 lowered the viral load of HIV patients; Hemispherx Biopharma reported that its immunomodulator added a synergistic effect to Tamiflu against asian flu; CV Therapeutics was lower after its angina treatment failed to win European approval; Biosite took a hit after warning that growth would slow; NxStage Medical, scheduled to price tonight, lowered its proposed range to $11-$12 from $13-$15; and Predix, which was scheduled to come public last week, formally withdrew its IPO offering. The Centient Biotech 200™ was lower by 13 points at 3732, a loss of .36%. More details...
